The Time in Therapeutic Range and Bleeding Complications of Warfarin in Different Geographic Regions of Turkey: A Subgroup Analysis of WARFARIN-TR Study

Salih Kılıç1, Ahmet Çelik2, Hüseyin Altuğ Çakmak3, Abdülmecit Afspın4, Ahmet İker Tekkeşin5, Gönül Açiksari6, Mehmet Erdem Memetoğlu7, Fatma Özpamuk Karadeniz8, Ekrem Şahan9, Mehmet Hayri Alici10, Yüksel Dereli11, Ümit Yaşar Sinan12, Mehdi Zoghi13

1Department of Cardiology, Ege University School of Medicine, İzmir, Turkey
2Department of Cardiology, Mersin University School of Medicine, Mersin, Turkey
3Clinic of Cardiology, Kağıt State Hospital, Rize, Turkey
4Department of Cardiology, İnönü University School of Medicine, Malatya, Turkey
5Clinic of Cardiology, Siyami Ersek Training and Research Hospital, İstanbul, Turkey
6Clinic of Cardiology, istinye State Hospital, istanbul, Turkey
7Clinic of Cardiovascular Surgery, Siyami Ersek Training and Research Hospital, İstanbul, Turkey
8Clinic of Cardiology, Balıklıgöl State Hospital, Şanlıurfa, Turkey
9Clinic of Cardiology, Atatürk Chest Disease and Chest Surgery Training and Research Hospital, Ankara, Turkey
10Clinic of Cardiology, 25 Aralık State Hospital, Gaziantep, Turkey
11Department of Cardiovascular Surgery, Necmettin Erbakan University Meram School of Medicine, Konya, Turkey
12Department of Cardiology, İstanbul University Institute of Cardiology, İstanbul, Turkey
13Department of Cardiology, Ege University School of Medicine, İzmir, Turkey

Background: The time in therapeutic range values may vary between different geographical regions of Turkey in patients vitamin K antagonist therapy.

Aims: To evaluate the time in therapeutic range percentages, efficacy, safety and awareness of warfarin according to the different geographical regions in patients who participated in the WARFARIN-TR study (The Awareness, Efficacy, Safety and Time in Therapeutic Range of Warfarin in the Turkish population) in Turkey.

Study Design: Cross-sectional study.

Methods: The WARFARIN-TR study includes 4987 patients using warfarin and involved regular international normalized ratio monitoring between January 1, 2014 and December 31, 2014. Patients attended follow-ups for 12 months. The sample size calculations were analysed according to the density of the regional population and according to Turkish Statistical Institute data. The time in therapeutic range was calculated according to F.R. Roosendaal’s algorithm. Awareness was evaluated based on the patients’ knowledge of the effect of warfarin and food-drug interactions with simple questions developed based on a literature review.

Results: The Turkey-wide time in therapeutic range was reported as 49.5%±22.9 in the WARFARIN-TR study. There were statistically significant differences between
Warfarin is an effective oral anticoagulant that is used for the prevention of thromboembolic events, especially in patients with atrial fibrillation (AF) and a prosthetic valve. Vitamin K antagonists (VKAs) reduce stroke by 64% compared to a placebo in patients with AF (1,2). The efficacy and safety of warfarin are dependent on maintenance of the international normalized ratio (INR). The target INR values alter according to the reason for warfarin use. The time in therapeutic range (TTR) should be above 70% for optimal efficacy and safety as well as to limit the risk of complications due to warfarin use (3-6). The risk of total mortality and major bleeding increases with irregular follow-up, an insufficient number of INR controls and/or a TTR value below 70% (3,5).

The TTR values may vary between countries in patients VKA therapy (7,8). In our country, the rate of TTR is lower than expected, and differences between geographical regions remain unknown for the time being (9-11). However, the ROCKET-AF study reported that TTR rates may vary among geographical regions (12).

In this study, the differences in TTR and their possible causes are examined in patients who participated in the WARFARIN-TR study (The Awareness, Efficacy, Safety and Time in Therapeutic Range of Warfarin in the Turkish Population) and used warfarin regularly for at least 12 months (9). In addition, the efficacy, safety and awareness of warfarin use were evaluated according to the different geographical regions in Turkey.

**MATERIALS AND METHODS**

The design, conduct and main results of the WARFARIN-TR study have been presented previously (9). In brief, the WARFARIN-TR study is a multicentre prospective observational study that included 42 centres from 24 cities in seven regions of Turkey. Patients (n=4987, mean age: 60.7±13.5 years, 44.9% male) attended follow-ups for 12 months. Out of the total number of patients, 2124 (42.6%) had a mechanical valve, 1918 (38.4%) had non-valvular AF and 985 (19%) had other conditions as warfarin indications, including chronic pulmonary embolism, ischaemic stroke, deep venous thrombosis, thrombus in any heart chamber, peripheral arterial thrombosis and rheumatic mitral stenosis with AF. The data, including key patient characteristics, treatment, concurrent illnesses and bleeding complications, were recorded.

The study protocol was approved by the local ethics committee. The patients’ data were obtained and recorded during routine clinical follow-up, and the INR values were recorded from the hospital records. Patients who were under 18 years of age, used warfarin inconsistently or did not attend INR monitoring sessions consistently were excluded from the study. The patients’ INR data were extracted for the period January 1, 2014 to December 31, 2014. Patients’ INR values were recorded between each measured INR. Patients with a time between any two measurements of ≥59 days (4.8% of the intervals between two INR measurements) were excluded from the TTR calculation and the study. TTR was calculated as the proportion of days with INR values between the target INR (2.0-3.0 or 2.5-3.5). The safety and efficacy of warfarin therapy are dependent on maintaining the INR with the target 2.0-3.0 for patients with non-valvular AF and other reason. The INR value target was 3 (2.5-3.5) in patients with a mechanical mitral valve and/or mechanical heart valves in both the aortic and mitral position (13). TTR was calculated according to F.R. Roosendaal’s algorithm with linear interpolation (14).

The awareness of warfarin use was evaluated by simple yes/no questions developed based on a literature review: “Do you know why you use warfarin?” and “Do you know anything about drug-food interactions with warfarin?” were the two questions asked (15).

Major bleeding was defined as a symptomatic bleeding in a critical organ, transfusion of two or more units of blood or a decrease in haemoglobin level of at least 2 g/L.
In this WARFARIN-TR substudy, the efficacy, safety and awareness of warfarin use were evaluated according to the different geographical regions in Turkey.

**Statistical analysis**

All the data were analysed using SPSS (Statistical Package for the Social Sciences) software for Windows Version 22.0. ANOVA was used to compare numerical variables between groups and for the subgroup comparisons least significant difference test. The relationship between categorical variables was tested by chi-square test to determine important factors of TTR values. General linear models were constructed and a multivariate logistic regression model was built for the bleeding dependent variable. The study sample was selected by stratified analysis according to the density of the regional population (Eastern Anatolia, South-eastern Anatolia, Central Anatolia, the Black Sea, Mediterranean, Aegean and Marmara) and according to Turkish Statistical Institute data (Table 1). P values of <0.05 were considered statistically significant.

**RESULTS**

**Risk scores:** There were statistically significant differences between regions in terms of CHA$^2$DS$_2$-VASc score, which showed the risk of stroke in patients with non-valvular AF (n=1918) (Table 2). The CHA$^2$DS$_2$-VASc score was statistically lower in South-eastern and Eastern Anatolia than in other regions. In addition, the scores for Marmara, the Aegean, the Black Sea and Central Anatolian regions were found to be similar and there was no statistically significant difference. A comparison of CHA$^2$DS$_2$-VASc scores between regions is summarized in Table 3. There were statistically significant differences between regions according to the HAS-BLED score, which indicates the risk of bleeding (Table 2). The bleeding score was reported to be significantly low in the South-eastern Anatolia, East Anatolia and Mediterranean regions, whereas the

| Region                  | Population distribution of provincial and district centres | Number of patients | % |
|-------------------------|------------------------------------------------------------|--------------------|---|
| Black Sea               | 8.500.000                                                  | 625                | 12.8|
| Marmara                 | 17.400.000                                                 | 1280               | 13.1|
| Aegean                  | 8.900.000                                                  | 655                | 17.1|
| Mediterranean           | 8.700.000                                                  | 640                | 9.0 |
| South-eastern Anatolia  | 6.600.000                                                  | 485                | 12.5|
| East Anatolia           | 6.100.000                                                  | 449                | 25.7|
| Central Anatolia        | 11.600.000                                                 | 853                | 9.7 |
| Total                   | 67.800.000                                                 | 4987               | 100|

| Region                  | Time in Therapeutic Range % | CHA$^2$DS$_2$-VASc | HAS-BLED | Bleeding rate % | Major bleeding |
|-------------------------|-----------------------------|---------------------|----------|-----------------|----------------|
| Marmara                 | 54.99±20.91                 | 2.62±1.59           | 1.82±1.26| 17.7            | 1.95           |
| Aegean                  | 54.65±24.21                 | 2.79±1.66           | 1.77±1.33| 21.7            | 5.11           |
| Mediterranean           | 51.44±25.32                 | 2.48±1.64           | 1.54±1.18| 21.7            | 1.71           |
| Black Sea               | 45.86±21.41                 | 2.68±1.54           | 2.01±1.18| 12.1            | 1.71           |
| Central Anatolia        | 45.47±19.97                 | 2.65±1.83           | 1.79±1.27| 13.8            | 3.20           |
| South-eastern Anatolia  | 44.37±23.54                 | 1.74±1.47           | 0.87±0.98| 3.84            | 3.98           |
| East Anatolia           | 41.95±24.15                 | 2.08±1.41           | 1.6±1.05  | 12.6            | 5.36           |

TTR: time in therapeutic range
bleeding score was significantly high in the Black Sea region. The bleeding scores of patients were similar in the Central Anatolia, Aegean and Marmara regions (Table 4).

**Time in therapeutic range**: Turkey-wide TTR was reported as 49.5%±22.9 in the WARFARIN-TR study. There were statistically significant differences between TTR according to different geographical regions of Turkey (Table 2). The TTR of the Marmara (54.99%±20.91) and Aegean (54.65±24.21) regions was similar and statistically higher than all other regions (p<0.001). Additionally, the TTR of South-eastern Anatolia (41.95±24.15) was close to that of East Anatolia (44.37±23.54) and significantly lower than other regions (p<0.001) (Table 5). Numerous parameters in the multivariate linear regression model were found to be effective on TTR. A low TTR was associated with female patients (compared to male; B=-1.32, p=0.044), a lack of knowledge of warfarin use (compared to good knowledge; B=3403, p=0.012), being uninformed about food-drug interactions (compared to informed; B=-4.807, p=0.001), chronic renal failure (compared to without chronic renal failure; B=-6569, p=0.001) and high risk scores of bleeding. In addition, TTR increased with aging (B=0.126, p=0.001), long duration of warfarin use (B=0.018, p=0.022) and CHA2DS2-VASc score (B=1.708, p=0.001) (Table 6). Also, the number of INR controls in a year and concomitant antiplatelet therapy were not found to be effective on TTR.

Regional differences were found to be effective on the TTR after purification of significant variables. The TTR was similar to the South-eastern Anatolia region (B=1.528, p=0.3) and significantly higher in the Marmara (B=13.1, p=0.001), Aegean (B=12.2, p=0.001), Mediterranean (B=9:01, p=0.001), Black Sea (B=7.15, p=0.001) and Central Anatolia (B=3.66, p=0.007) regions when the Eastern Anatolia region was considered as a reference.

**Awareness and bleeding**: The proportion of patients who knew why they were using warfarin was 81.9% in the whole country and only 55% of patients were informed about food and drug interactions. The proportion of patients who knew why they were using warfarin was statistically higher in the Aegean, Anatolia and Central Anatolia (respectively 91.0%, 90.4% and 88.4%) regions; on the other hand, it was similar in the Mediterranean and Marmara regions (respectively 82.7% and 81.1%) and significantly lower in the South-eastern and Black Sea regions (respectively 75.4% and 60.2%). The proportion of patients who were informed about food and drug interactions was statistically higher in the Aegean and Central Anatolian regions (respectively 68.4% and 68.3%), whereas it was lower in the Black Sea and South-eastern Anatolia regions (respectively 30.1% and 31.5%).

There were statistically significant differences between regions in terms of all-cause bleedings and major bleedings (Table 2). Minor bleedings were frequently observed in all regions. All-cause bleedings were significantly higher in the East Anatolia (41.6%) and lower in the South-eastern Anatolia (12.6%) region. Regional differences had an effect on all-cause bleedings and residence in the East Anatolia had a higher risk of bleeding after purification of significant variables (Table 7). Major bleeding was significantly higher in the Aegean (5.11%) and South-eastern Anatolia (5.36%) and less frequent in the East Anatolia (1.78%), Mediterranean (1.71%) and Marmara (1.95%) regions. Additionally, major bleeding was observed to be nearly three times higher in the Aegean region than in

**Table 4. Comparison of HAS-BLED scores between regions**

|          | Aegean | Mediterranean | Black Sea | Central Anatolia | South-eastern Anatolia | East Anatolia |
|----------|--------|---------------|-----------|------------------|------------------------|--------------|
| Marmara  | 0.386  | 0.001*        | 0.001*    | 0.593            | 0.001*                 | 0.001*       |
| Aegean   | 0.001* | 0.001*        | 0.222     | 0.720            | 0.001*                 | 0.022*       |
| Mediterranean | 0.001* | 0.001*        | 0.001*    | 0.001*           | 0.448                  |              |
| Black Sea | 0.001* | 0.001*        | 0.001*    | 0.001*           | 0.001*                 |              |
| Central Anatolia | 0.001* | 0.001*        | 0.001*    | 0.001*           | 0.006*                 |              |
| South-eastern Anatolia | 0.001* | 0.001*        | 0.001*    | 0.001*           | 0.002*                 |              |

*p<0.05

**Table 5. Comparison of time in therapeutic range rates according to regions**

|          | Aegean | Mediterranean | Black Sea | Central Anatolia | South-eastern Anatolia | East Anatolia |
|----------|--------|---------------|-----------|------------------|------------------------|--------------|
| Marmara  | 0.752  | 0.001*        | 0.001*    | 0.001*           | 0.001*                 | 0.001*       |
| Aegean   | 0.010* | 0.001*        | 0.001*    | 0.001*           | 0.001*                 | 0.001*       |
| Mediterranean | 0.001* | 0.001*        | 0.001*    | 0.001*           | 0.001*                 | 0.001*       |
| Black Sea | 0.742  | 0.275         | 0.001*    | 0.001*           | 0.001*                 | 0.005*       |
| Central Anatolia | 0.391  | 0.007*        | 0.001*    | 0.001*           | 0.100                  |              |
| South-eastern Anatolia | 0.001* | 0.001*        | 0.001*    | 0.001*           | 0.001*                 |              |

*p<0.05
Eastern Anatolia (OR 3.13 95% CI 1:14-8:56 p=0.02) and four times higher in the South-eastern Anatolia region (OR: 4.18 95% CI 1.53-11.4 p=0.005) (Table 8) in the multivariate logistic regression analysis, which evaluated risk factors that may affect major bleedings. In addition, in the same analysis both all-cause bleeding and major bleeding were observed to be higher in patients undergoing concomitant antiplatelet therapy (respectively OR: 1.381 95% CI 1.157-1.648 p=0.001; OR: 1.527 95% CI 1.041-2.239 p=0.030).

**DISCUSSION**

The WARFARIN-TR study is important in terms of involving patients that represented the overall population of Turkey from all regions and evaluated all-cause warfarin users. Data from the WARFARIN-TR study was evaluated in terms of TTR percentages, efficacy, safety and awareness of warfarin use according to different geographical regions in Turkey. Our study provides national data about TTR for all warfarin users (mechanical valve, non-valvular AF, other conditions) and first time for mechanical

| Table 6. Results of general linear model to determine important factors for time in therapeutic range values |
|---------------------------------------------------------------|
| Variables | B | Standard error | p |
| Age | 0.126 | 0.032 | 0.001* |
| Gender (female vs male) | -1.327 | 0.658 | 0.044* |
| Patients with knowledge of warfarin utilization reason vs not | -3.407 | 1.359 | 0.012* |
| Patients with knowledge of food-drug interaction vs not | -4.807 | 0.716 | 0.001* |
| Duration of warfarin utilization | 0.018 | 0.008 | 0.022* |
| CHA2DS2-VASc score | 1.708 | 0.304 | 0.001* |
| HAS-BLED score | -5.710 | 0.376 | 0.001* |
| One-year follow-up of INR values | -0.083 | 0.101 | 0.407 |
| Patients receiving antiaggregant and not | -1.121 | 0.801 | 0.162 |
| Patients with chronic renal failure and not | -6.569 | 1.359 | 0.001* |
| Marmara vs East Anatolia | 13.109 | 1.338 | 0.001* |
| Aegean vs East Anatolia | 12.239 | 1.489 | 0.001* |
| Mediterranean vs East Anatolia | 9.013 | 1.432 | 0.001* |
| Black Sea vs East Anatolia | 7.158 | 1.451 | 0.001* |
| Central Anatolia vs East Anatolia | 3.669 | 1.370 | 0.007* |
| South-eastern Anatolia vs East Anatolia | 1.528 | 1.545 | 0.323 |

INR: international normalized ratio

| Table 7. Multivariate logistic regression results to determine important factors of bleeding |
|---------------------------------------------------------------|
| Variables | OR | 95% CI for OR | p |
| Age | 0.990 | 0.983 | 0.998 | 0.010* |
| Gender (female vs male) | 0.959 | 0.895 | 1.028 | 0.237 |
| Patients with chronic renal failure vs not | 1.054 | 0.788 | 1.410 | 0.722 |
| Patients with knowledge of warfarin utilization reason vs not | 1.299 | 0.960 | 1.759 | 0.090 |
| Patients with knowledge of food-drug interaction vs not | 1.004 | 0.850 | 1.186 | 0.962 |
| Duration of warfarin utilization | 1.006 | 1.004 | 1.007 | 0.001* |
| HAS-BLED Score | 1.444 | 1.327 | 1.571 | 0.001* |
| One-year follow-up of INR values | 1.021 | 0.998 | 1.045 | 0.079 |
| Patients receiving antiaggregant and not | 1.381 | 1.157 | 1.648 | 0.001* |
| Marmara vs East Anatolia | 0.422 | 0.321 | 0.555 | 0.001* |
| Aegean vs East Anatolia | 0.447 | 0.328 | 0.609 | 0.001* |
| Mediterranean vs East Anatolia | 0.369 | 0.272 | 0.501 | 0.001* |
| Black Sea vs East Anatolia | 0.262 | 0.190 | 0.363 | 0.001* |
| Central Anatolia vs East Anatolia | 0.346 | 0.260 | 0.460 | 0.001* |
| South-eastern Anatolia vs East Anatolia | 0.264 | 0.185 | 0.379 | 0.001* |

*p<0.05; INR: international normalized ratio; OR: odds ratio; CI: confidence interval
The TTR values were higher in Italy (69.5%) and Spain (64.9%), where patients were followed by special anticoagulation clinics, than in general clinics in the US (58.1%), Canada (62.8%) and France (59.3%). In a similar study, which assessed a one-year INR follow-up of patients in specific (n=233) and general clinics (n=148) in our country, the mean TTR was significantly higher in the specific clinic group (19). Although the outcomes of our study and other studies in Turkey were consistent with the general polyclinic results of this study, specific polyclinic results were significantly higher. Specific clinics may overcome this problem in regions of Turkey with low TTR.

Awareness is the most prominent factor for effective drug therapy in patients. Low TTR outcomes in our study and other studies in Turkey could be explained by a lack of knowledge of warfarin use in nearly one-fifth of patients and drug-food interactions in nearly half of the patients nationwide. Additionally, the high rate of knowledge about drug-food interactions in regions with a high TTR supports this finding. In multivariate analysis, the presence of awareness has a constant impact on TTR. In addition, according to cohort studies, with aging, long-term use of warfarin TTR increases and our results were consistent with these results (20,21).

Bleeding rates, an indicator of reliability, were found to be higher in the overall country and minor bleeding was observed more frequently. Although bleeding risk scores were significantly different between regions, all patients had a low bleeding profile. The statistically significant differences between the regions and ongoing observation of these differences in the multivariate analysis in terms of both all-cause bleeding and major bleeding showed that geographical differences have a marked influence on bleeding in Turkey, just like TTR. However,
socio-economic, ethnic and cultural differences may also have an effect on bleeding among regions. The combination of VKA and antiplatelet therapy is associated with both increased all-cause bleeding and major bleeding compared with VKA monotherapy. In multivariate analysis, we showed that both all-cause bleeding and major bleeding are significantly increased in a combination of VKA and antiplatelet therapy. The main limitation of our study is that we did not record embolic complications at follow-up. In conclusion, statistically significant differences were reported in terms of the efficacy, safety and awareness of warfarin therapy according to different geographical regions in Turkey. However, these differences may have emerged due to other reasons such as socio-economic, cultural and ethnic differences that were not assessed in the present study. Therefore, further researches should be performed with larger study groups to achieve more accurate results.

Acknowledgements
The authors who have contributed to the preparation of this manuscript; Elif Çekirdekçi, Servet Altay, Deniz Elıcık, Nazlı Akçiğer, Eyüp Özkan, Mine Durukan, Yusuf Aslantaş, Bahadır Şarlı, Çağrı Yayla, Murat Bilgın, Kadri Akboğa, Tolga Han Ef, Ali Sabri Seyis, Zeynep Yapan Emren, Kamil Tuluçe, Nurullah Çetin, Ali Kemal Kalkan, Fatih Aytemiz, Selen Yakar Tuluçe, Mehmet Kiş, Ahmet Güneş, Özge Kurmuş, Seyda Günay, Hamza Duygu, Özcan Başaran, Sinan Inci, Mehmet Balli, Öżgen Şafak, Fatma Köksal, Barış Celebi, Buğra Özkan, Murat Bitezker, Hasan Yücel, Yakup Altaş, Selim Topçu, Emrah Yeşıl, Tuğba Kemaloğlu Öz, Ali Zorlu, Lütfü Aşkın, Kerem Özbek, Volkan Emren, Kaya Özen, Servet İzci, Mehmet Ali Kobat, Ahmet Hakan Ateş, Abdülkadir Çakmak, Yasin Çakilli. We thank for the contributions.

Financial Disclosure: No financial disclosure was declared by the authors.

Conflict of Interest: No conflict of interest was declared by the authors.

REFERENCES
1. Hylek EM, Go AS, Chang Y, Jensvold NG, Henault LE, Selby JV, et al. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. New Engl J Med 2003;349:1019-26.
2. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007;146:857-67.
3. White HD, Gruber M, Feyzi J, Kaatz S, Tse HF, Husted S, et al. Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulant control: results from SPORTIF III and V. Arch Intern Med 2007;167:239-45.
4. Camm AJ, Lip GY, De Caterina R, Savelieva I, Atar D, Hohnloser SH, et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J 2012;33:2719-47.
5. Gallagher AM, Setakis E, Plumb JM, Clemens A, van Staa TP. Risks of stroke and mortality associated with suboptimal anticoagulation in atrial fibrillation patients. Thromb Haemost 2011;106:968.
6. Cove CL, Hylek EM. An updated review of target-specific oral anticoagulants used in stroke prevention in atrial fibrillation, venous thromboembolic disease, and acute coronary syndromes. J Am Heart Assoc 2013;2:e000136.
7. Pengo V, Pegoraro C, Cucchinì U, Iliceto S. Worldwide management of oral anticoagulant therapy: the ISAM study. J Thromb Thrombolysis 2006;21:73-7.
8. Molteni M, Cinminiello C. Warfarin and atrial fibrillation: from ideal to real the warfarin affair. Thromb J 2014;12:1.
9. Çelik A, İzci S, Kobat MA, Ateş AH, Çakmak A, Çakilli Y, et al. The awareness, efficacy, safety, and time in therapeutic range of warfarin in the Turkish population: WARFARIN-TR. Anatol J Cardiol 2016;16:595-600.
10. Ertas F, Kaya H, Kaya Z, Buluş S, Köse N, Gül M, et al. Epidemiology of atrial fibrillation in Turkey: preliminary results of the multicenter AFTER study. Turk Kardiyol Dern Ars 2013;41:99-104.
11. Turk UO, Tuncer E, Alioglu E, Yuksel K, Pekel N, Ozpelt E, et al. Evaluation of the impact of warfarin time in therapeutic range on outcomes of patients with atrial fibrillation in Turkey: Perspectives from the observational, prospective WATER Registry. Cardiol J 2015;22:567-75.
12. Singer DE, Hellkamp AS, Piccini JP, Mahaffey KW, Lokhnygina Y, Pan G, et al. Impact of global geographic region on time in therapeutic range on warfarin anticoagulant therapy: data from the ROCKETF clinical trial. J Am Heart Assoc 2013;2:e000067.
13. Guyatt GH, Akı EA, Crowther M, Guterman DD, Schuürmann HJ; American College of Chest Physicians Antithrombotic Therapy and Prevention of Thrombosis Panel. Executive summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141(2 Suppl):7-47.
14. Rosendaal FR, Cannegieter SC, Van der Meer FJ, Briet E. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost 1993;69:236-9.
15. Wang Y, Kong MC, Lee LH, Ng HJ, Ko Y. Knowledge, satisfaction, and concerns regarding warfarin therapy and their association with warfarin adherence and anticoagulation control. Thromb Res 2014;133:559-40.
16. Asarcliiker LD, Şen T, İpek EG, Kafes H, Cebeci M, Gül M, et al. Time in therapeutic range (TTR) value of patients who use warfarin and factors which influence TTR. J Am Coll Cardiol 2013;62:127-8.
17. Cressman AM, Macdonald EM, Yao Z, Austin PC, Gomes T, Paterson JM, et al. Socioeconomic status and risk of hemorrhage during warfarin therapy for atrial fibrillation: A population-based study. Am Heart J 2015;170:133-40.
18. Sakarya A, İbüşoğlu Ç. Türkiye’de ilerlen sosyo-ekonomik gelişmişlik endeksinin coğrafi ağırlıklı regresyon modeli ile analizi. Marmara Coğrafiya Dergisi 2015:211-38.
19. Kilic S YE, Simsek E, Yagmur B, Cevdet M, Metin G, et al. Prospective observational comparison of TRW in patients followed by specialized INR outpatient clinic and by the general cardiology outpatient clinic. Anatol J Cardiol 2015;15(Suppl 1):1-104.
20. Okumura K, Komatsu T, Yamashita T, Okuyama Y, Harada M, Konta Y, et al. Time in the therapeutic range during warfarin therapy in Japanese patients with non-valvular atrial fibrillation-A multicenter study of its status and influential factors. Circ J 2011;75:2087-94.
21. Dött JS, George RA, Huang X, Odeh M, Kaufman HW, Ansell J, et al. A national assessment of warfarin anticoagulation therapy for stroke prevention in atrial fibrillation. Circulation 2014;129:1407-14.